Stevens-Johnson syndrome and toxic epidermal necrolysis: Consequence of treatment of an emerging pathogen

Pediatric Emergency Care

Volumn 25, Issue 8, 2009, Pages 519-522

  Mistry, Rakesh D ^a,b   Schwab, Sandra H ^a,b   Treat, James R ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Methicillin resistant Staphylococcus aureus; Stevens Johnson syndrome; Toxic epidermal necrolysis; Trimethoprim sulfamethoxazole

Indexed keywords

COTRIMOXAZOLE; IMMUNOGLOBULIN; MORPHINE;

ADOLESCENT; ARTICLE; BODY RASH; CASE REPORT; CELLULITIS; DYSURIA; FEVER; HEADACHE; HUMAN; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NECK PAIN; PAIN; PAINFUL DEFECATION; PHYSICAL EXAMINATION; SORE THROAT; SPEECH DISORDER; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; VISUAL DISORDER;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CELLULITIS; COMMUNICABLE DISEASES, EMERGING; COMMUNITY-ACQUIRED INFECTIONS; DIAGNOSTIC ERRORS; EPIDERMAL NECROLYSIS, TOXIC; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PNEUMONIA; RECURRENCE; SCARLET FEVER; SEPSIS; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; STEVENS-JOHNSON SYNDROME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 69549124796     PISSN: 07495161     EISSN: None     Source Type: Journal    
DOI: 10.1097/PEC.0b013e3181b0a49a     Document Type: Article

References (40)

1. Lyell A. Toxic epidermal necrolysis (the scalded skin syndrome): a reappraisal. Br J Dermatol. 1979;100(1):69-86. (Pubitemid 9255482)
2. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331(19):1272-1285. (Pubitemid 24333193)
3. French LE, Trent JT, Kerdel FA. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. Int Immunopharmacol. 2006;6(4):543-549. (Pubitemid 43295459)
4. French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int. 2006;55(1):9-16.
5. Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92-96.
6. Leaute-Labreze C, Lamireau T, Chawki D, et al. Diagnosis, classification, and management of erythema multiforme and Stevens-Johnson syndrome. Arch Dis Child. 2000;83(4):347-352. (Pubitemid 30744779)
7. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149-153. (Pubitemid 30637181)
8. Ducic I, Shalom A, Rising W, et al. Outcome of patients with toxic epidermal necrolysis syndrome revisited. Plast Reconstr Surg. 2002;110(3):768-773. (Pubitemid 34855940)
9. Schulz JT, Sheridan RL, Ryan CM, et al. A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil. 2000;21(3):199-204. (Pubitemid 30396349)
10. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333(24):1600-1607.
11. Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol. 1990;126(1):43-47.
12. Hernborg A. Stevens-Johnson syndrome after mass prophylaxis with sulfadoxine for cholera in Mozambique. Lancet. 1985;2(8463):1072-1073. (Pubitemid 16206775)
13. Miller KD, Lobel HO, Satriale RF, et al. Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis. Am J Trop Med Hyg. 1986;35(3):451-458.
14. Roujeau JC, Guillaume JC, Fabre JP, et al. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985. Arch Dermatol. 1990;126(1):37-42.
15. Schopf E, Stuhmer A, Rzany B, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol. 1991;127(6):839-842.
16. Frazee BW, Lynn J, Charlebois ED, et al. High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann Emerg Med. 2005;45(3):311-320. (Pubitemid 40261163)
17. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med. 2005;352(14):1436-1444. (Pubitemid 40471451)
18. Kaplan SL, Hulten KG, Gonzalez BE, et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis. 2005;40(12):1785-1791. (Pubitemid 40799948)
19. Moran GJ, Amii RN, Abrahamian FM, et al. Methicillin-resistant Staphylococcus aureus in community-acquired skin infections. Emerg Infect Dis. 2005;11(6):928-930. (Pubitemid 40720855)
20. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355(7):666-674. (Pubitemid 44244537)
21. Purcell K, Fergie J. Epidemic of community-acquired methicillin-resistant Staphylococcus aureus infections: a 14-year study at Driscoll Children's Hospital. Arch Pediatr Adolesc Med. 2005;159(10):980-985. (Pubitemid 41423339)
22. Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. Jama. 1998;279(8):593-598. (Pubitemid 28110205)
23. Zaoutis TE, Toltzis P, Chu J, et al. Clinical and molecular epidemiology of community-acquired methicillin-resistant Staphylococcus aureus infections among children with risk factors for health care-associated infection: 2001-2003. Pediatr Infect Dis J. 2006;25(4):343-348.
24. Centers for Disease Control and Prevention. Community-associated methicillin-resistant Staphylococcus aureus infection among healthy newborns - Chicago and Los Angeles County, 2004. MMWR Morb Mortal Wkly Rep. 2006;55(12):329-332.
25. Jemni L, Hmouda H, Letaief A. Efficacy of trimethoprim-sulfamethoxazole against clinical isolates of methicillin-resistant Staphylococcus aureus: a report from Tunisia. Clin Infect Dis. 1994;19(1):202-203. (Pubitemid 24227061)
26. Frank AL, Marcinak JF, Mangat PD, et al. Community-acquired and clindamycin-susceptible methicillin-resistant Staphylococcus aureus in children. Pediatr Infect Dis J. 1999;18(11):993-1000.
27. Frank AL, Marcinak JF, Mangat PD, et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J. 2002;21(6):530-534. (Pubitemid 34625834)
28. Centers for Disease Control and Prevention. Severe Clostridium difficile-associated disease in populations previously at low risk-four states, 2005. MMWR Morb Mortal Wkly Rep. 2005;54(47):1201-1205.
29. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect. 1998;40(1):1-15. (Pubitemid 28438966)
30. Libertin CR, Wold AD, Washington JA 2nd. Effects of trimethoprim- sulfamethoxazole and incubation atmosphere on isolation of group A streptococci. J Clin Microbiol. 1983;18(3):680-682.
31. Gorwitz RJ, Jernigan DB, Powers JH, et al. Strategies for Clinical Management of MRSA in the Community: Summary of an Experts' Meeting Convened by the Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/ncidod/dhqp/ar-mrsa-ca.html. Accessed October 12, 2006.
32. King MD, Humphrey BJ, Wang -F, et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med. 2006;144(5):309-317.
33. Miller LG, Spellberg B. Treatment of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections with drainage but no antibiotic therapy. Pediatr Infect Dis J. 2004;23(8):795. (Pubitemid 39063306)
34. Lee MC, Rios AM, Aten MF, et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin- resistant Staphylococcus aureus. Pediatr Infect Dis J. 2004;23(2):123-127.
35. Llera JL, Levy RC. Treatment of cutaneous abscess: a double-blind clinical study. Ann Emerg Med. 1985;14(1):15-19. (Pubitemid 15161258)
36. Macfie J, Harvey J. The treatment of acute superficial abscesses: a prospective clinical trial. Br J Surg. 1977;64(4):264-266. (Pubitemid 8075132)
37. Paydar KZ, Hansen SL, Charlebois ED, et al. Inappropriate antibiotic use in soft tissue infections. Arch Surg. 2006;141(9):850-854. (Pubitemid 44414426)
38. Rajendran PM, Young D, Maurer T, et al. randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother. 2007;51(11):4044-4048.
39. Gonzalez BE, Hulten KG, Dishop MK, et al. Pulmonary manifestations in children with invasive community-acquired Staphylococcus aureus infection. Clin Infect Dis. 2005;41(5):583-590. (Pubitemid 41170343)
40. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. Jama. 2007;298(15):1763-1771. (Pubitemid 47598444)